Phase 3 trial of K-924 HD in adults with hypercholesterolemia inadequately controlled on pitavastatin 4 mg

Phase 3, randomised, double-blind trial in hypercholesterolemia comparing K-924 HD + pitavastatin with ezetimibe + pitavastatin (2 arms). Primary endpoints: Percent change from baseline in LDL-C at Week 12 and Adverse events and adverse drug reactions. Planned start Apr 2026; status: authorised.